For the roughly 8,000 people living with Huntington’s disease in the UK, a rare and fatal genetic disorder, progress has been painfully slow—until now.
Recent research has shown that a novel gene therapy could significantly slow disease progression, offering long-awaited hope for patients and families.
How the Breakthrough Happened
The treatment, known as AMT-130, is the first gene therapy tested in people with Huntington’s disease.
A clinical study led by the life sciences company uniQure, and supported by the National Institute for Health and Care Research (NIHR), revealed that participants receiving a higher dose experienced 75% slower disease progression over three years, with improvements in movement and cognitive decline.
This milestone demonstrates how combining expert science advice, publicly funded research infrastructure, and industry collaboration can turn innovative ideas into tangible results for patients.
The Role of NIHR in Supporting Research
The NIHR played a central role in making this breakthrough possible:
- Biomedical Research Centres and Clinical Research Facilities provided specialist NHS facilities, expert advice, and highly trained staff.
- The NIHR Research Delivery Network supplied additional research personnel and supported a long-term observational study to provide a comparison group of patients not receiving the therapy.
By ensuring rigorous scientific oversight and robust data collection, NIHR helped validate the therapy’s effectiveness and safety.
Strengthening the UK’s Life Sciences Leadership
This Huntington’s study is just one example of the NIHR’s impact. In a single year, its research infrastructure enabled nearly 18,000 projects, spanning medicine, public health, and social care.
By linking trusted scientific advice, the NHS, and industry partners, NIHR not only accelerates the development of new treatments but also reinforces the UK’s position as a global hub for life sciences innovation.
Impact and Consequences
The introduction of AMT-130 could have wide-reaching effects:
- Slows progression of a previously untreatable, fatal condition.
- Improves quality of life for patients and families over several years.
- Sets a precedent for using gene therapies in other neurodegenerative diseases.
- Strengthens confidence in UK clinical research and regulatory oversight.
- Demonstrates the value of public investment in research infrastructure for national health and innovation.
What’s Next?
- Follow-up studies will continue to monitor long-term safety and effectiveness.
- Efforts are underway to expand patient access to the therapy within NHS clinical trials.
- Researchers will explore similar gene therapy approaches for other rare and genetic conditions.
- NIHR will continue providing science advice and infrastructure support to accelerate future breakthroughs.
Summary
A coordinated effort between NIHR, the NHS, and industry has made it possible to slow the progression of Huntington’s disease for the first time.
AMT-130 represents a landmark gene therapy breakthrough, demonstrating the critical role of science advice, public research infrastructure, and collaboration in turning innovative ideas into real-world treatments.
Bulleted Takeaways
- AMT-130 is the first gene therapy tested for Huntington’s disease in humans.
- High-dose recipients showed 75% slower disease progression over three years.
- NIHR provided facilities, research staff, and scientific guidance to ensure robust results.
- A long-term observational study provided comparison data to validate findings.
- Nearly 18,000 NIHR-enabled projects illustrate the UK’s research capacity.
- The therapy improves both motor and cognitive function in patients.
- Demonstrates how public investment in science infrastructure accelerates life-changing treatments.
